Development of pemphigus vulgaris following mRNA SARS‐CoV‐19 BNT162b2 vaccination in an 89‐year‐old patient.

The patient has provided written consent for the publication of the case. Most PV patients are aged 40-60 years at diagnosis.1 The mean age of pemphigus patients was 62.5 years in the Swiss cohort.3 However, the development of PV after COVID-19 vaccination may be simply coincidental in our patient. Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient. [Extracted from the article]